



## BioNTech Recognizes Employees and Partners for Their Support in Developing Historic Vaccine

December 31, 2020

**MAINZ, Germany, December 31, 2020** — [BioNTech SE](#) (Nasdaq: BNTX) today wants to express its thanks and gratitude not only to its employees but also to the many partners who have assisted the company in successfully developing a vaccine for COVID-19. BioNTech acknowledges that without the tireless effort from its' employees and partners, who have played a pivotal role in this effort, it would not have been able to achieve this historic company milestone, a journey which only began in early 2020. Data from its Phase 3 study have demonstrated that the vaccine is well-tolerated and 95% effective in preventing COVID-19. The vaccine has already received conditional marketing authorizations as well as emergency use authorizations in more than 45 countries around the world, including the United States and the European Union.

BioNTech's employees have made a significant contribution to this initiative, working around the clock to harness the power of mRNA and apply it to this effort of fighting against the devastating pandemic. In addition, our partner companies and organizations have provided the company with research expertise, critical supply support, and valuable insights and assistance throughout the development and trial process. Without them, achieving this result only 11 months after the initiation of Project Lightspeed would not have been possible.

"To address a global challenge like COVID-19, we have undertaken a worldwide effort to develop a well-tolerated and effective vaccine as quickly as science and cutting-edge technology will allow," said **Ugur Sahin, M.D., CEO and Co-founder of BioNTech**. "Despite the damage caused by the virus, I have been inspired each day by the spirit of collaboration and scientific discovery. It is one of the greatest honors of my life to be involved in this effort and to play a role in helping the world regain a sense of normality. I would like to thank each and every person that helped make this a reality."

BioNTech's management and employees appreciate the relentlessly support of many companies. A full list of BioNTech's partners supporting the COVID-19 project can be found below and at this [link](#).

### Our Partners:

A-C	D-L	M-P	Q-Z
A&C Biobuffer	D-HCC Dopamine Healthcare Communication	MACHEREY-NAGEL	QIAGEN
Acuitas	Dätwyler Holding	Marble Pharma Consult	Ragon Institute of MGH, MIT and Harvard
Admedicum	Delpharm	Medidata	Ramsay Pharma
Agilent Technologies Sales & Services	Dermapharm	medwiss-extern	RD-Biotech
Alexis Carpenter Consulting	DHL	Merck	Real Life Sciences
ALFA Chemicals	Discovery Life Sciences	Merck Chemicals	Regeneron
Almac Clinical Services	Dr. Liebscher Consulting	Meso Scale Diagnostics	Rentschler
Applied Critical Fluids	Dunn Labortechnik	Miltenyi Biotec	Sartorius Lab Instruments
Aristo Pharma	Entourage Pharma Consulting	MLM Medical Labs	Sartorius Stedim Biotech
auceris	Eppendorf Vertrieb Deutschland	mpütranslations	Schott
Avanti Polar Lipids	Eurobio Scientific	Mundicare	Siegfried
Avia Pharma	Eurofins Genomics Germany	nerbe plus	Sigma-Aldrich Chemie
Baxter	Evonik Industries	New England Biolabs	Sino Biological Europe
Becton Dickinson	Finsbury Glover Hering Corporation	National Institutes of Health (NIH)	Sinus Event-Technik
Bexon Clinical Consulting	Fisher Scientific	Novartis	Staburo
Biaffin	Fosun Pharma	ONE LOGIC	Stephenson Harwood
BioCat	FreshFields Bruckhaus Deringer	ORIGIO Clinical Monitoring	Stevenato Group
BioLegend Europe	Gowling WLG	Osborne Clarke	SyroCon Consulting
Biomay	Granzer Regulatory Consulting & Service	Panhans Pharma Consult	Tecan Deutschland

Biotrend Chemikalien	Greiner Bio-One	Paul Hastings	Thermo Fisher Scientific
Biozol Diagnostica Vertrieb	GlaxoSmithKline (GSK)	Pfizer	THERON Management Advisors
Brand Institute	Hölzel Diagnostika Handels	PharmaCentaur	Topmedicare
Carl Roth	Horváth & Partner	PHARM-SOFT Dr. B. Rodus	TriLink BioTechnologies
Catalent	ICON	PHMR	TriRadial Solutions
CG Pharma	Informa Pharma Intelligence	Phoenix-Apotheke Mainz	TRON
Charles River Laboratories	Instadeep	Pixilicious Enterprises	Trophic Communications
Charles River Microbial Solutions International	JANVIER LABS	Plan@ IT Services	Universitätsklinikum Frankfurt
Chemengineering	K-Recruiting	Polymun	UniversitätsKlinikum Heidelberg
Choate Hall & Stewart	Kerafast	portvier	VisMederi
CMS Legal Services	Kissel Pharma Consulting	Powell Gilbert	VWR International
Cognigy	LGC Genomics	Precision Bioservices	WE Communications
Cole-Parmer	Life Technologies (Thermo Fisher Scientific)	Precision for Medicine	World Courier
Consulimus	LKF-Laboratorium für Klinische Forschung	Profishop-Bremen	ZSP Patentanwälte
Corning	LPT Laboratory of Pharmacology and Toxicology	ProfiLab24	
Covington		Progressive Recruitment	
CRB Group		pure 11	
Croda International		PriceWaterhouseCoopers (PwC)	
CRS Clinical Research Services Mannheim			

### About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit [www.BioNTech.de](http://www.BioNTech.de).

### BioNTech Contacts:

#### Media Relations

Jasmina Alatovic  
+49 89 62 81 75 46  
[Media@biontech.de](mailto:Media@biontech.de)

#### Investor Relations

Sylke Maas, Ph.D.  
+49 (0)6131 9084 1074  
[Investors@biontech.de](mailto:Investors@biontech.de)